NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Regenxbio, Inc. provided investors with false and/or misleading information regarding the efficacy and safety of its trial study for RGX-111, a one-time gene therapy for the treatment of Hurler Syndrome, including positive assertions of RGX-111’s future trial success based on continuing positive biomarker and safety data from the ongoing Phase I/II study.
If you currently own RGNX and purchased prior to February 9, 2022 please contact Sophia Anne Silayan by email at sophiaanne@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814
